4-pentanoyloxy-aniline | 55536-09-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 4-pentanoyloxy-aniline
• 英文别名: (4-Aminophenyl) pentanoate
• CAS: 55536-09-9
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: HWJLACGYFCNYPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 2-(5-巯基-1,3,4-恶二唑-2-基)苯酚 、 4-pentanoyloxy-aniline 以 乙醇 为溶剂， 生成 5-(2-hydroxy-phenyl)-3-(4-pentanoyloxy-anilinomethyl)-3H-[1,3,4]oxadiazole-2-thione
  参考文献：
  名称：

  Ram,V.J.; Pandey,H.N., Journal of the Indian Chemical Society, 1974, vol. 51, p. 634 - 635

  摘要：

  DOI：

文献信息

• PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT
  申请人：Ashikawa Masanori

  公开号：US20120004197A1

  公开（公告）日：2012-01-05

  Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin. Specifically disclosed is and EPO production enhancer and/or a hemoglobin production enhancer comprising a 1-acyl-4-(substituted oxy, substituted amino, or substituted thio)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by general formula (1) [wherein R 1 , R 2 , R 2′ , R 3 and R 3′ independently represent a hydrogen atom, a C 1-6 alkyl group, or the like; R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 independently represent a hydrogen atom, a halogen atom, a C 1-6 alkyl group, or the like; A represents N—R 11 , a sulfur atom, or an oxygen atom; R 11 represents a hydrogen atom, a C 1-6 alkyl group, or the like; B represents a C 6-14 aryl group, or a 5- to 10-membered heterocyclic group; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.

  揭示了一种具有低分子量的化合物，具有增强EPO产生和/或增强血红蛋白产生活性的化合物。具体揭示了一种EPO产生增强剂和/或血红蛋白产生增强剂，包括1-酰基-4-(取代氧基、取代氨基或取代硫基)-1,2,3,4-四氢喹啉衍生物，更具体地说是由通式(1)表示的四氢喹啉化合物【其中R1、R2、R2'、R3和R3'独立地表示氢原子、C1-6烷基或类似物；R4、R5、R6、R7、R8、R9和R10独立地表示氢原子、卤素原子、C1-6烷基或类似物；A表示N—R11、硫原子或氧原子；R11表示氢原子、C1-6烷基或类似物；B表示C6-14芳基或5-至10-成员杂环基；n表示0或1的整数】，四氢喹啉化合物的盐，或四氢喹啉化合物或其盐的溶剂化合物。
• [EN] NUCLEOSIDE TRIPHOSPHATE AND NUCLEOSIDE TRIPHOSPHATE ANALOGUE PRODRUGS<br/>[FR] PROMÉDICAMENTS DE NUCLÉOSIDE TRIPHOSPHATE ET D'ANALOGUES DE NUCLÉOSIDE TRIPHOSPHATE
  申请人：UNIV HAMBURG

  公开号：WO2018100137A1

  公开（公告）日：2018-06-07

  The invention relates to nucleoside triphosphate and nucleoside triphosphate analogue prodrugs. It is an object of the present invention to provide improved nucleoside triphosphate or nucleoside triphosphate analogue prodrugs. To achieve the object, the present invention provides in one aspect non-symmetrically double modified nucleoside triphosphate compounds, or their analogues, wherein the modification is carried out at the terminal, i.e. the γ-phosphate, or the corresponding analogous group, and wherein the first modification is adding a moiety A being intracellular stable, and the second modification is adding an intracellular labile mask B, which is cleaved within the cell, such that a nucleoside triphosphate or analogue thereof mono-modified with the intracellularly stable moiety A is released in the cell.

  本发明涉及核苷酸三磷酸和核苷酸三磷酸类似物前药物。本发明的目的是提供改进的核苷酸三磷酸或核苷酸三磷酸类似物前药物。为了实现这一目的，本发明在一方面提供非对称双修饰核苷酸三磷酸化合物或其类似物，其中修饰在末端即γ-磷酸基或相应的类似基团处进行，第一修饰是添加细胞内稳定的基团A，第二修饰是添加细胞内不稳定的掩蔽基团B，在细胞内被裂解，从而释放出一个单修饰细胞内稳定基团A的核苷酸三磷酸或其类似物。
• Novel opioid peptides for the treatment of pain
  申请人：AstraZeneca AB

  公开号：US20030032774A1

  公开（公告）日：2003-02-13

  This invention relates to opioid peptides, to pharmaceutical compositions containing the peptides, and to methods for controlling pain by administering the peptides or pharmaceutical compositions. The peptides have a high degree of selectivity for the &mgr;-opioid receptor. Although they are highly lipophilic, the peptides do not readily cross the blood brain barrier (BBB). Because the peptides act peripherally, they substantially avoid the side effects associated with central analgesic action.

  本发明涉及阿片肽、含有该肽的药物组合物以及通过施用该肽或药物组合物控制疼痛的方法。多肽对阿片受体具有高度选择性。虽然多肽具有很高的亲脂性，但并不容易穿过血脑屏障（BBB）。由于多肽作用于外周，它们大大避免了与中枢镇痛作用相关的副作用。
• US4124579A
  申请人：——

  公开号：US4124579A

  公开（公告）日：1978-11-07
• US8791090B2
  申请人：——

  公开号：US8791090B2

  公开（公告）日：2014-07-29